Two major C-terminal variants ending at Val40 and Ala42 constitute the majority of amyloid ␤-protein (A␤), which undergoes postsecretory aggregation and deposition in the Alzheimer disease (AD) brain. To probe the differential pathobiology of the two A␤ variants, we used an in vivo paradigm in which freshly solubilized A␤1-40 or A␤1-42 was injected into rat brains, followed by examination using Congo red birefringence, A␤ immunohistochemistry, and electron microscopy. In the rat brain, soluble A␤ 1-40 and A␤1-42 formed aggregates, and the A␤1-40 but not the A␤1-42 aggregates showed Congo red birefringence. Electron microscopy revealed that the A␤1-40 aggregates contained fibrillar structures similar to the amyloid fibrils of AD, whereas the A␤1-42 aggregates contained nonfibrillar amorphous material. Preincubation of A␤1-42 solution in vitro led to the formation of birefringent aggregates, and after injection of the preincubated A␤1-42, the aggregates remained birefringent in the rat brain. Thus, a factor or factors might exist in the rat brain that inhibit the fibrillar assembly of soluble A␤1-42. To analyze the postsecretory processing of A␤, we used the same in vivo paradigm and showed that A␤1-40 and A␤1-42 were processed at their N termini to yield variants starting at pyroglutamate, and at their C termini to yield variants ending at Val40 and at Val39. Thus the normal rat brain could produce enzymes that mediate the conversion of A␤ 1-40/1-42 into processed variants similar to those in AD. This experimental paradigm may facilitate efforts to elucidate mechanisms of A␤ deposition evolving into amyloid plaques in AD.
Deposition of amyloid ␤-protein (A␤) as amyloid fibrils or nonfibrillar amorphous aggregates in senile plaques characterizes the Alzheimer disease (AD) brain. There are two types of senile plaques, i.e., diff use and dense-cored plaques. The diffuse plaques are composed of nonfibrillar amorphous A␤ aggregates that are not associated with degenerative changes, whereas the cored plaques contain abundant A␤ fibrils that are associated with pathological changes in the surrounding brain parenchyma (for review, see Selkoe, 1994) .
A␤ peptides that are composed of 39 -43 amino acids derived from the amyloid ␤-protein precursor (APP) (Kang et al., 1987) are produced as soluble metabolic products of the APP, and they are constitutively secreted into culture medium and cerebrospinal fluids (Haas et al., 1992; Shoji et al., 1992) . The majority of the secreted soluble A␤ species includes A␤1-40 and A␤1-42, which start at Asp1 and end at either Val40 or Ala42, respectively (Vigo-Pelfrey et al., 1993; Suzuki et al., 1994) .
In the AD brain, these soluble A␤ peptides undergo aggregation and are deposited as several variants. The major N-terminal A␤ variants include A␤N1, which bears the standard N terminus, and A␤N3(pE), which bears an N-terminal pyroglutamate (Mori et al., 1992; Saido et al., 1995 Saido et al., , 1996 . Deposition of the A␤N3(pE) prevails at higher density than the A␤N1 and precedes that of the A␤N1 in plaques (Saido et al., 1995) . The major C-terminal variants include A␤C40 and A␤C42, which retain C-terminal amino acids identical to those of the secreted A␤1-40 and A␤1-42, respectively (Mori et al., 1992; Miller et al., 1993; Roher et al., 1993a,b) . In the parenchymal amyloid deposits, A␤C42 is deposited in greater density than A␤C40 (Iwatsubo et al., 1994 , although soluble A␤1-40 is more abundantly secreted than soluble A␤1-42 (Seubert et al., 1992; Dovey et al., 1993; Vigo-Pelfrey et al., 1993; Suzuki et al., 1994) . Thus, these distinct A␤ species seem to be metabolized differently and may play different roles in the deposition of A␤.
Previous in vitro studies have provided important information on the pathobiology of A␤1-40 and A␤1-42 and their relevance to the pathological processes in AD, but there has been little effort to extend these studies to the in vivo brain environment of experimental animals. In view of the fact that conditions in vitro and in vivo are quite different, and given the remarkable discrepancies between the apparent toxicity of A␤ peptides in vitro versus in vivo, it is important to undertake in vivo studies of the fate of A␤ peptides. Therefore, we used an in vivo paradigm in which A␤1-40 or A␤1-42 was injected into rat brain to dissect their differential pathobiology in AD. Herein we demonstrate that A␤1-40 and A␤1-42 differ in their ability to form amyloid fibrils in vivo as well as in the postinjection processing at their C termini. Notably A␤1-40 but not A␤1-42 was competent to form amyloid fibrils in vivo. In addition, A␤1-42 was subjected to rapid Cterminal proteolysis, whereas the C -terminal proteolysis of A␤1-40 was delayed. Thus, this animal model could be used to understand the fibrillogenesis of and postsecretory processing of A␤ in AD.
MATERIALS AND METHODS
Human analog peptides corresponding to A␤1-40 and A␤1-42 were synthesized by solid phase methods on an Applied Biosystems (Foster C ity, CA) synthesizer Model 430A according to the manufacturer's procedures. The synthesized peptides were purified by C18 reverse-phase HPLC with the corresponding standards obtained from Bachem (Torrance, CA) for comparison. The synthesized peptide samples co-eluted with the corresponding standards, indicating identity with each other. The A␤ samples were verified f urther by amino acid sequencing. The A␤ peptides were lyophilized as stock sample and used throughout the following experiments.
The lyophilized samples were freshly solubilized in 0.15 M Tris buffer, pH 8.8, filtered (0.22 m), and adjusted to 10 g/l (referred to hereafter as "freshly solubilized" A␤1-40 and A␤1-42) immediately before each injection. Five microliters of these A␤1-40 (10 g/l) or A␤1-42 (10 g/l) were injected into the right side of the hippocampus or deep cerebral cortex of female Sprague Dawley rats (200 -300 gm; n ϭ 50). After different postinjection survival times, the brains removed from the rats were fixed in 70% ethanol /0.15 M NaC l and embedded in paraffin as reported previously (Shin et al., 1993 (Shin et al., , 1994 . The postinjection survival times included 1 d (n ϭ 5), 1 week (n ϭ 5), 3 weeks (n ϭ 5), 5 weeks (n ϭ 5), and 7 weeks (n ϭ 5) for A␤1-40 as well as for A␤1-42. Paraffin sections were examined by Congo red staining and immunohistochemistry using several antibodies that specifically recognize different epitopes in A␤. The antibodies used here are summarized in Table 1 . The anti-C39 was newly produced in a rabbit against a synthetic peptide C M VGGV to which keyhole limpet hemocyanin was conjugated, and was affinity-purified as described previously (Saido et al., 1995) . Its specificity was confirmed by dot and Western analyses using A␤1-39, A␤1-40, A␤1-41, A␤1-42, and A␤1-43 peptides. Immunostaining of AD sections using the anti-C39 antiserum revealed that A␤C39 is present in diff use and cored plaques of the AD brain. 4G8 was used to recognize authentic A␤, regardless of its processing at the N or C terminus. Anti-N1D and anti-N3(pE) were used to analyze N-terminal processing of A␤, and BC05, anti-C42, BA27, anti-C40, and anti-C39 were used to analyze C -terminal processing of A␤.
For electron microscopic study, the same amounts of the freshly solubilized A␤1-40 (10 g/l) and A␤1-42 (10 g/l) were injected into the right and left sides of the same rat brain (n ϭ 18), respectively. After different postinjection survival times, the rats were perf used with PBS, followed by perf usion with 4% glutaraldehyde/0.1 M cachodylate buffer, pH 7.4, as described (Shin et al., 1993) . The postinjection survival times included 1 week (n ϭ 8), 2 weeks (n ϭ 5), and 3 weeks (n ϭ 5). The brains were removed, cut coronally, and dissected into small blocks that contained the injection sites. The blocks were f urther fixed in 1% osmium tetroxide and then dehydrated through a graded series of ethanol, immersed in propylene oxide, and embedded in Epoxy resin. One micrometer semithin sections were cut and stained with toluidine blue. Selected areas were thin-sectioned with a diamond knife, stained with uranyl acetate and lead citrate, and examined with a Hitachi H-7000 electron microscope at 75 kV as reported previously (Kondo et al., 1996) .
The A␤ peptides were tested to determine whether they were competent to assemble into fibrils in vitro under conditions that are known to favor A␤ fibrillogenesis as described previously (L orenzo and Yankner, 1994) , with minor modification. Briefly, 10 mg of the A␤ stock samples was dissolved in double-distilled water, filtered (0.22 m), and diluted with the same volume of PBS to 350 M. The same amount of A␤1-42 was dissolved in double-distilled water, filtered (0.22 m), and adjusted to 350 M. The A␤ solutions were incubated at 37°C for 5 d, followed by centrif ugation at 30,000 ϫ g for 20 min. The resultant pellet was resuspended in PBS to 10 g/l (referred to hereafter as "in vitro preincubated" A␤1-40 and A␤1-42). Aliquots of these samples were plated onto poly-L-lysine-coated glass plates, dried, stained with Congo red, and viewed under polarized microscopy. Other aliquots of the in vitro preincubated A␤1-40 and A␤1-42 peptides were also used for injection into rat brains (n ϭ 40) and examined as described above, with postinjection survival times of 1 d (n ϭ 5), 1 week (n ϭ 5), 3 weeks (n ϭ 5), and 5 weeks (n ϭ 5) for A␤1-40 as well as for A␤1-42. In addition, the A␤1-40 and A␤1-42 peptides were freshly solubilized in the same buffer and in the same concentration as those that were used for injection into rat brain to test f urther the ability of these peptides to undergo fibrillogenesis in vitro. After incubation at 37°C for 5 d, the A␤ samples were plated onto poly-L-lysine-coated glass plates and examined as described above.
RESULTS
The near-serial sections through the injection sites in the rat brains were immunostained with 4G8 (Figs. 1 A,D, 3A ,D, 4A,E) to document the location of the injected material. The A␤1-40 and A␤1-42 samples that were soluble before injection formed 4G8-positive aggregates in the rat brain at the earliest postinjection survival time (1 d) (Figs. 1 D, 3A ,D, 4A,E). Although these aggregates persisted for a prolonged period, they were cleared from the rat brains by ϳ5-7 weeks postinjection. Thus, in the experimental system used here, the temporal profiles of aggregation, persistence, and clearance of the injected A␤ peptides were the same for A␤1-40 and A␤1-42, except that the abundance of the A␤1-40 aggregates was greater than the A␤1-42 aggregates at the temporal stage between injection and final clearance.
Although it is plausible that endogenous rodent A␤ species contribute to the A␤ aggregates detected here, there were significant differences in the immunohistochemical and histochemical profile of the aggregates induced by injections of A␤1-40 versus A␤1-42. Thus, for simplicity, we consider the immunohistochemical and other data described here to be a consequence of the injected human A␤.
Freshly solubilized A␤1-40 but not A␤1-42 is assembled into amyloid fibrils in rat brain
The in vivo paradigm of extracellular injection of freshly solubilized A␤s in rat brain was analyzed for the ability of these peptides to assemble into amyloid fibrils. The rat brain sections including the A␤ aggregates were stained with Congo red. The A␤1-40 aggregates demonstrated intense birefringence under polarized microscopy ( Fig. 1 B) , indicating the formation of amyloid fibrils by the A␤1-40 peptides. The birefringence in the A␤1-40 aggregates appeared at 1 d postinjection survival time, and this birefringence persisted until the aggregates were cleared away by 5-7 weeks postinjection survival times (not shown). In contrast, the aggregates formed by the A␤1-42 peptides were not birefringent after Congo red staining at any of the postinjection survival times (Fig. 1 E) , indicating that these peptides did not form amyloid fibrils.
To confirm that the birefringent A␤ aggregates contained amyloid fibrils, we performed electron microscopy on sections of rat brains injected with freshly solubilized A␤ peptides. In the right side of the rat brains injected with A␤1-40 peptides, 5-10 nm fibrillar structures were observed (Fig. 2 A,B) that appeared similar to the fibrils seen in amyloid plaques of the AD brain. However, in the left side of the rat brains injected with A␤1-42 peptides, only amorphous material was found (Fig. 2C,D) . Thus, these electron microscopic studies demonstrate that freshly solubilized A␤1-40, but not A␤1-42, is assembled into amyloid fibrils after injection into the rat brain, consistent with the results obtained by the examination using Congo red birefringence.
Because previous in vitro experiments showed that both A␤1-40 and A␤1-42 peptides self-assemble into amyloid fibrils (Fraser et al., 1992; Bush et al., 1994; L orenzo and Yankner, 1994; Ma et al., 1994) , and biophysical experiments indicated that A␤1-42 forms amyloid fibrils even more readily than A␤1-40 , we examined the ability of each of the species of A␤ peptides to form amyloid fibrils in vitro under two different conditions, as described in Materials and Methods. After incubation under each condition, we observed that both A␤1-40 and A␤1-42 peptides formed Congo red-stained birefringent aggregates (Fig. 1C,F ) , indicating that they assembled into amyloid fibrils. Thus, A␤1-40 is competent to form amyloid fibrils in vitro and in vivo, whereas A␤1-42 is competent to form amyloid fibrils in vitro but not in vivo.
To examine the in vivo properties of these A␤1-40 and A␤1-42 fibrils generated in vitro, we injected aliquots of these fibrillar A␤ samples into rat brains, and we observed aggregates of these A␤ fibrils that persisted in abundance much more than aggregates of A␤ that formed after injection of freshly solubilized A␤ samples at all postinjection survival times examined (1 d to 5 weeks). The aggregates of in vitro preincubated A␤1-40 and A␤1-42 were intensely birefringent after Congo red staining (not shown), and they appeared similar to those produced with injections of freshly solubilized A␤1-40 (Fig. 1 B) .
In vivo N-and C-terminal processing of freshly solubilized A␤1-40 and A␤1-42
To gain insights into the postsecretory processing of A␤1-40 and A␤1-42 in the in vivo brain, we next examined whether freshly solubilized A␤s injected into the rat neocortex and hippocampus were modified as were A␤ deposits in amyloid plaques of the AD brain. For this purpose, we performed immunohistochemistry using antibodies that specifically recognize different N-terminal variants of A␤, including A␤1N and A␤N3(pE), as well as Cterminal variants of A␤, including A␤C42, A␤C40, and A␤C39, on rat brain sections containing aggregates of the A␤ peptides (see Table 1 for a summary of the specificities of these antibodies). The A␤ aggregates were positively immunostained with the anti-N1 as well as with the anti-N3(pE) antibodies as early as 1 d postinjection (Fig. 3B,C,E,F ) . Because aggregates of injected A␤1-40 and A␤1-42 were promptly processed at their N termini to yield the A␤N3(pE) variant similar to A␤ deposited in amyloid plaques of the AD brain (Mori et al., 1992; Saido et al., 1995 Saido et al., , 1996 , both A␤1-40 and A␤1-42 appear to be equally susceptible to this modification. Furthermore, the A␤1-42 aggregates were positively immunostained with the BA27, the anti-C40, and the anti-C39 antibodies at the earliest postinjection survival time (1 d) (Fig. 4 F-H ) , suggesting that injected A␤1-42 peptides underwent rapid C-terminal proteolysis to yield A␤C40 and A␤C39. In contrast, the aggregates of injected A␤1-40 were not immunostained with the anti-C39 at 1 d postinjection survival time (Fig.  4C ), but were positively immunostained with this antibody at 1-3 weeks postinjection survival times (Fig. 4 D) . This suggests that injected A␤1-40 yielded A␤C39 after a more attenuated process of C-terminal proteolysis. Thus, A␤1-40 and A␤1-42 are processed at their C termini, but this processing occurs more rapidly for A␤1-42 than for A␤1-40.
DISCUSSION
In 1987, Kang et al. first reported biochemical evidence that A␤1-42/43 consists of the neuritic plaques (Kang et al., 1987) . In 1993, Jarret and Lansbury suggested the "seeding" hypothesis wherein A␤1-42 serves as a seed for plaque formation and A␤1-40 is incorporated later as A␤ progressively deposits in the AD brain . Since then, considerable attention has focused on the differential amyloidogenic capabilities of A␤ species with variable C termini, especially the A␤C40 and A␤C42 variants. Indeed, support for this concept has come from immunohistochemical studies (Iwatsubo et al., 1994 conducted with antibodies that specifically recognize A␤C40 versus A␤C42 . For example, in the brains of patients with AD or Down's syndrome, A␤C42 is deposited before A␤C40, and A␤C42 is the predominant species of A␤ in amyloid plaques at all stages of these diseases. Furthermore, prominent accumulations of A␤C42 are seen in the diffuse plaques that are thought to represent an early stage in the formation of amyloid plaques, whereas accumulations of A␤C40 are more characteristic of the cored plaques that are believed to form later in the process of amyloidogenesis. A␤17-42 is a unique proteolytic fragment of A␤ in that it is biochemically extractable from the diffuse plaques but not from the cored plaques (Gowing et al., 1994) . Taken together, these observations suggest that A␤C40 and A␤C42 may play distinct roles in the progressive deposition of A␤ in the AD brain.
The studies described here were designed to gain insight into the differential pathobiology of A␤1-40 versus A␤1-42 in the brains of living mammals. To this end, we studied synthetic A␤1-40 or A␤1-42 peptides that were injected into the neocortex and hippocampus of rats, and we showed here that these A␤ variants exhibited striking differences in their ability to form amyloid fibrils. Specifically, fibrils were generated consistently from A␤1-40 but not from A␤1-42. Although previous in vivo studies (Rush et al., 1992; Snow et al., 1994) reported the formation of amyloid fibrils in the rat brain after injections of A␤1-40, and other in vivo studies (Waite et al., 1992 ) of injections of A␤1-42 failed to produce amyloid fibrils, our study is novel because it directly assessed the differential amyloidogenic capabilities of these two important species of A␤ in vivo, and this has enabled us to reconcile a critical discrepancy in the literature on amyloidogenesis in the AD brain. Indeed, our data are consistent with studies showing that A␤C42 dominates in diffuse plaques with few amyloid fibrils (Yamaguchi et al., 1989; Davies and Mann, 1993; Iwatsubo et al., 1994 Iwatsubo et al., , 1995 , whereas A␤C40 is most prominent in cored plaques with abundant amyloid fibrils (Iwatsubo et al., 1994 . Thus our observations on the preferential contribution of A␤1-40 to the formation of A␤ fibrils in the rat brain suggest the these findings may reflect authentic molecular events underlying the fibrillogenesis of A␤ in the AD brain. It should be emphasized, however, that these findings do not contradict the putative role of A␤1-42 in the pathogenesis of AD; this A␤ variant is shown to be the earliest and most abundant species of A␤ deposited in the amyloid-rich senile plaques in AD brains, and the production of more A␤1-42 has been linked to the onset of familial AD attributable to mutations in the presenilin and APP genes (Hardy, 1997) . Therefore, initial deposition of A␤1-42 is a necessary early pathological process, but it is not sufficient to develop mature amyloid plaques unless succeeded by further deposition of A␤1-40. Although A␤1-42 failed to form fibrils in vivo as we observed in the present experimental animal system, it spontaneously assembled into fibrils after preincubation in vitro, and this is consistent in turn with previous in vitro studies (Lorenzo and Yankner, 1994; Ma et al., 1994; Buscioglio et al., 1995) . The mechanism that accounts for this differential assembly of A␤1-42 into fibrils in vitro but not in vivo is currently unknown, but it is plausible that a factor or factors exist in the rat brain that inhibit the assembly of A␤1-42 into amyloid fibrils. However, such factors do not induce A␤1-42 fibrils formed in vitro to disassemble after injection into the rat brain, because these A␤1-42 fibrils retained their Congo red birefringence for prolonged intervals in vivo. On the basis of the data reported here, we speculate that our model system could be used to identif y factors that prevent the assembly of soluble A␤1-42 into amyloid fibrils in the mammalian brain. For example, cells of the macrophage/microglia lineage and glial cells in the brain could secrete such factors into the extracellular space because these cells accumulate around plaques in the AD brain and appear to intermingle preferably with the A␤1-42 aggregates in the rat brain (our unpublished results). Lending support for this hypothesis, a recent in vitro study showed that microglia adhere to fibrillar A␤1-42 via their scavenger receptors, followed by secretion of reactive oxygen species from the microglia, leading to clearance of the fibrillar A␤1-42 (K houry et al., 1996) . Because in vitro experiments (Lorenzo et al., 1994) suggest that the neurotoxicity of A␤ is mediated by the fibrillar rather than the amorphous forms of the peptides, and fibril-rich amyloid plaques induce the most reactive changes in the AD brain, the assembly of A␤ into fibrils rather than the mere accumulation of A␤ as amorphous deposits in the extracellular space may be a critical event that leads to the degeneration of neurons in AD. Thus, the model system described here may enable the elucidation of the mechanisms that regulate the acquisition of A␤ neurotoxicity via fibrillogenesis in the AD brain.
In view of current uncertainties about the biological consequences of A␤ deposition in the AD brain, it is important to elucidate the mechanisms that regulate production, aggregation, and proteolysis of A␤. The model system described here could be used to unravel the molecular basis of the postsecretory processing of A␤. In the rat brain, injected A␤1-40 and A␤1-42 were similarly processed at their N termini to yield A␤N3(pE), whereas they were processed differently at their C termini where A␤1-42 was rapidly processed to yield A␤C40 and A␤C39, but the proteolysis of A␤1-40 to yield A␤C39 occurred more slowly. Taken together, these data suggest that the normal rat brain secretes enzymes that differentially process A␤1-40 and A␤1-42 to yield A␤N3(pE), A␤C40, and A␤C39. Thus, the N-and Cterminal processing of A␤ occurs in the rat brain, and this processing is not a pathological process unique to the AD brain. Additional studies of the processing and fate of human A␤ peptides injected into the rodent brain may clarify the mechanisms responsible for fibrillogenesis and neurodegenerative processes in the AD brain.
